rs12659 — SLC19A1

Synonymous variant in the folate transporter SLC19A1 — a haplotype tag linked to altered methotrexate response

See your personal result for SLC19A1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC19A1 rs12659 — A Haplotype Tag in the Folate Gateway

The reduced folate carrier (RFC1, encoded by SLC19A1) is the principal route by which folates and antifolate drugs — including methotrexate — enter most human cells. Like any well-studied transporter gene, SLC19A1 carries a cluster of common variants that tend to travel together in haplotype blocks. rs12659 (Pro232Pro; 6318C>T on the coding strand) is one of four variants that define the second linkage disequilibrium block of SLC19A1, the others being rs1051266, rs1131596, and rs3788200.

The Mechanism

rs12659 itself is a synonymous variant11 synonymous variant
A synonymous variant changes the DNA sequence but not the amino acid — the codon changes from one proline codon to another at position 232. Because the amino acid is unchanged, the variant does not directly alter transporter structure or function. Its clinical relevance comes primarily from its role as a haplotype tag: the A allele (plus-strand notation, corresponding to the coding-strand T allele) tags a specific version of the SLC19A1 gene that co-occurs with other functional variants in the same block, most prominently the transport-reducing rs1051266 T allele. This is why rs12659 signals in studies even though it encodes no protein change.

Synonymous variants can theoretically affect mRNA stability, splicing efficiency, or translation speed through codon-usage effects, and this possibility has been raised for SLC19A1 rs12659. However, direct experimental evidence for such a mechanism at this specific position is currently lacking.

The Evidence

Individual-SNP analysis in a pilot study of 100 Chinese rheumatoid arthritis patients receiving methotrexate found that rs12659 G allele carriers had significantly better clinical response: Cen et al. 202222 Cen et al. 2022
Cen H et al. Associations Between Genetic Polymorphisms Within Transporter Genes and Clinical Response to Methotrexate in Chinese Rheumatoid Arthritis Patients. Pharmacogenomics Pers Med, 2022 reported RR=1.42 (95% CI=1.02–1.97, P=0.04) for EULAR good/moderate response under a dominant model (G/G + A/G vs A/A). Haplotype analysis in the same study showed the TGAA haplotype (carrying the A allele at rs12659 together with the rs1051266-T transport-reducing allele) was associated with worse MTX response (OR=0.37, 95% CI=0.14–0.98), indicating the haplotype effect is primarily driven by rs1051266.

In a separate study of 122 lung cancer cases vs 122 matched controls in Xuan Wei, China — a population with exceptionally high lung cancer rates attributed to indoor coal smoke — Shen et al. 200533 Shen et al. 2005
Shen M et al. Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung Cancer, 2005 found the Pro232Pro C allele (plus-strand G allele) associated with increased lung cancer risk (OR=1.83, 95% CI=1.02–3.28). This finding requires caution: the sample was small, the population was exposed to an unusually potent carcinogen, and the result has not been replicated in non-coal-smoke contexts.

A PharmGKB pharmacogenomics summary44 PharmGKB pharmacogenomics summary
Gong L et al. SLC19A1 Pharmacogenomics Summary. Pharmacogenet Genomics, 2010 notes that the Pro232Pro variant did not show a significant association with non-Hodgkin lymphoma across 1,000+ cases and controls, and showed a positive association with cervical carcinoma platinum-based chemotherapy response in one study, suggesting tissue- and drug-specific effects.

Practical Actions

Because rs12659 is a synonymous haplotype tag rather than a functional variant, it does not independently indicate any specific dietary or supplementation change. Its primary clinical value is as a marker that travels with the folate transport-modifying rs1051266 allele. Individuals homozygous for the A allele at rs12659 are very likely to also carry the rs1051266 T allele, meaning the folate transport considerations for that variant apply — principally, preferring methylfolate (5-MTHF) over synthetic folic acid and ensuring adequate cellular folate intake.

For patients taking methotrexate for rheumatoid arthritis, inflammatory bowel disease, or oncological indications, rs12659 A-allele homozygosity — as part of the TGAA haplotype context — may signal a need for closer monitoring of clinical response and folate status, since the linked rs1051266-T allele reduces cellular uptake of both folate and methotrexate.

Interactions

rs12659 is in strong linkage disequilibrium with rs1051266 (the functionally characterized G80A/His27Arg variant already profiled separately), rs1131596 (5'-UTR), and rs3788200 (intronic). In the four-SNP TGAA haplotype block, the dominant signal appears driven by rs1051266 — the transporter's known functional variant. Because this platform already profiles rs1051266 directly, rs12659 adds independent information only when an individual carries a discordant haplotype (rs12659-A without rs1051266-T, or vice versa), which is rare given the high LD between them.

Pathway-level interactions with MTHFR rs1801133 and MTHFD1 rs2236225 operate at the level of rs1051266's transport function, not rs12659 per se.

Drug Interactions

methotrexate altered_efficacy literature

Nutrient Interactions

folate altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG High Transport Haplotype Normal

Common genotype — associated with normal folate transporter haplotype

You carry two copies of the G allele at rs12659, the most common variant globally (~58% frequency). This allele tags the SLC19A1 haplotype associated with normal folate transport efficiency and, in studies of methotrexate-treated patients, with better clinical response. About 34% of people carry this genotype (GG homozygous).

AG Intermediate Haplotype Intermediate

One A allele — partial tag for the reduced-transport haplotype

The A allele at rs12659 tags a specific SLC19A1 haplotype that mildly reduces cellular folate transport capacity on one chromosome. One copy of the reduced-transport haplotype roughly halves the effect seen in A/A homozygotes — typically a 10–20% reduction in intracellular folate delivery, which is usually compensable through adequate dietary folate or methylfolate supplementation.

For methotrexate pharmacogenomics, heterozygosity at rs12659 typically has a smaller effect than A/A homozygosity, consistent with the dominant model reported by Cen et al. 2022 (RR=1.42 for G-dominant vs A-homozygote comparison).

AA Reduced-Transport Haplotype Reduced

Homozygous A allele — both chromosomes carry the reduced-transport SLC19A1 haplotype

The A allele at rs12659 marks a specific SLC19A1 haplotype in which both gene copies are in the reduced-transport configuration. This means your cellular folate import capacity is reduced on both chromosomes — a double burden on folate delivery that compounds any dietary insufficiency.

A small lung cancer study in an indoor coal smoke-exposed Chinese population (Shen et al. 2005, PMID 15922487) reported the G allele (the common allele) at OR=1.83 for lung cancer risk in that specific context — the opposite direction from other associations — suggesting that the cancer-risk signal is environmental-exposure dependent and not generalizable to low-coal-smoke populations. Do not interpret the A/A genotype as protective against lung cancer.

For methotrexate pharmacogenomics, A/A homozygosity may contribute to reduced drug uptake into cells, potentially requiring dose adjustment or closer monitoring of drug response and toxicity markers. This should be interpreted together with rs1051266 status for a complete picture.